HPV status and staging in oropharyngeal carcinoma: A review of recent AJCC/UICC revisions

Abstract

The incidence of oropharyngeal carcinoma (OPC) has been rising, particularly among HPV-positive patients, prompting a reevaluation of clinical staging practices. Recent revisions to the AJCC/UICC staging systems have recognized the distinct biological behavior associated with HPV-positive tumors, highlighting the necessity for tailored staging criteria that better reflect their unique prognostic characteristics. This review discusses the implications of HPV status on the clinical staging of oropharyngeal carcinoma, focusing on how these revisions influence prognosis and treatment strategies. The differential outcomes observed between HPV-positive and HPV-negative patients necessitate a more nuanced approach to management, advocating for personalized treatment plans that consider the specific tumor biology. Additionally, we explore the ongoing research efforts aimed at further refining staging criteria, including the identification of relevant biomarkers and the integration of advanced imaging techniques. As our understanding of HPV's role in cancer biology continues to evolve, it is imperative that our approaches to staging and management adapt accordingly. Ultimately, these revisions and the accompanying research will contribute to improved patient outcomes and more effective therapeutic interventions in the increasingly prevalent landscape of oropharyngeal carcinoma.